Immuneering Corp — Director's Dealing 2021

Jul 30, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2021-07-29

Reporting Person: Barrett Scott (Chief Medical Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option	$3.01	2029-12-15	Class A Common Stock (194740)		Direct
Series A Preferred Stock	$		Class A Common Stock (3273)		Direct
Series B Preferred Stock	$		Class A Common Stock (2723)		Direct

Footnotes

F1: The option vests and becomes exercisable as to 25% of the underlying shares on November 11, 2020 and then in equal monthly installments over the subsequent three years, subject to Dr. Barrett's continued employment through each applicable vesting date.

F2: Each share of the Issuer's preferred stock is convertible on a one-for-one basis into shares of the Issuer's Class A common stock in certain circumstances and has no expiration date. The preferred stock will automatically convert into Class A common stock immediately prior to the closing of the Issuer's initial public offering.